During Tuesday’s trading session, the shares of an integrated global pharmaceutical company, headquartered in Hyderabad, slumped nearly 3.4 percent on BSE, after reporting a fire incident in the company’s Andhra Pradesh manufacturing facility.
Price Movement
With a market cap of Rs. 70,445.4 crores, at 03:29 p.m., the shares of Aurobindo Pharma Limited were trading in the red at Rs. 1,212.9 on BSE, down by around 2.7 percent, as compared to its previous closing price of Rs. 1,246.75.
The stock has delivered positive returns of over 5 percent in one year, and gained about 7 percent in the last one month.
What’s the News
According to the latest regulatory filings with the stock exchanges, Aurobindo Pharma Limited reported that a fire incident occurred on April 27, 2025, at around 10:00 PM in the vicinity of the coal crusher area at its Penicillin-G manufacturing facility located in the Kakinada SEZ, Thondangi (M), Andhra Pradesh.
The incident took place at Lyfius Pharma Private Limited due to the self-ignition of coal. The company is currently in the process of determining the exact cause of the fire.
The incident caused damage to certain ancillary equipment; however, the core manufacturing infrastructure remained unaffected. No injuries were reported, and the event is not expected to have a material impact on the group’s operations or financial performance.
Aurobindo Pharma further stated that a thorough assessment of the damage is underway, while the loss/damage is covered by insurance. As a precautionary measure, and to facilitate the replacement of necessary equipment, operations at the plant will be temporarily suspended for an estimated period of 20 to 25 days.
Financial Performance
Aurobindo Pharma reported a marginal growth in revenue from operations, experiencing a year-on-year increase of nearly 8.5 percent, rising from Rs. 7,352 crores in Q3 FY24 to Rs. 7,979 crores in Q3 FY25.
In contrast, during the same period, its net profit decreased from Rs. 940 crores to Rs. 846 crores, representing a decline of around 10 percent YoY.
About the company
Aurobindo Pharma Limited is principally engaged in the business of manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals and related services.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
